NM283: Interim Phase IIa data

Interim 4-week data from an ongoing, open-label, U.S. Phase IIa trial in 12 treatment-naïve patients showed a 99.8% reduction in NM283 plus pegylated interferon group compared to NM283 alone. The tria...